Is a good buy iova now before report?

Iovance Biotherapeutics (IOVA) does not appear to be a strong buy at this time, considering the upcoming earnings report and the current financial metrics. Here's why:

1. Recent Earnings History: IOVA has reported losses in the last four quarters, with the most recent quarter's earnings per share (EPS) being -$0.424. The upcoming earnings report is expected to show a further loss of -$0.35 per share.

2. Stock Price Reaction to Earnings: The stock has experienced a significant decline of 18.51% the day after the last earnings announcement. This suggests that the market may react negatively to another earnings report showing a loss.
3. Analyst Ratings and Price Targets: Despite the negative earnings history, analysts have a strong buy consensus with an average price target of $23.71, indicating a potential upside. However, this should be weighed against the current trading price of $7.94.

4. Financial Health Concerns: The company's recent earnings surprises have been mixed, with one beat and one miss. Additionally, the company has a history of negative EPS growth and has not yet reported a profit.
5. Market Sentiment: The stock has been described as a "sell candidate" with a high risk profile, suggesting that investors may be cautious about buying ahead of the earnings report.

In conclusion, while there is potential upside according to analysts, the recent earnings history, stock price reactions, and negative EPS trends suggest that IOVA may not be a good buy before the upcoming earnings report. Investors should exercise caution and consider these factors before making an investment decision.